Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Nine-year follow-up of HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy
GERMS, Volume 3, No. 3, Year 2013
Notification
URL copied to clipboard!
Description
Introduction Many Romanian children were infected nosocomially with human immunodeficiency virus (HIV) in the late 1980s. The Romanian-American Children's Center of Excellence in Constanta continues to follow approximately 450 of these patients. In 2001, 414 of these patients were initiated on triple therapy including lopinavir/ritonavir. Data from this cohort treated through August 2006 were published in April 2007 demonstrating that the treatment was well tolerated, with 337 children (81%) remaining on therapy after a median duration of >4 years. The current article describes the results of continued analysis of this cohort through end 2010. The objective of the study was to determine the long-term clinical outcomes of children and adolescents commenced on antiretroviral therapy (ART) including lopinavir/ritonavir. Methods Data were extracted retrospectively from the charts of the 336 patients remaining on lopinavir/ritonavir in August 2006. The following outcomes were analyzed: mortality, current patient status, viral load (VL), CD4 counts and reasons for discontinuation of lopinavir/ritonavir. Results The median age at initiation of lopinavir/ritonavir was 14.0 years (range 5.4 to 20.0 years). The median time on lopinavir/ritonavir treatment was 7.5 years (interquartile range 5.7 to 8.6 years). Overall mortality was 13.5%. Of the original 414 patients started on lopinavir/ritonavir in 2001, 199 (48.1%) remained on this therapy at the end of 2010 and of these 63.8% had undetectable viral load. Conclusion Despite initial suboptimal ART, a significant proportion of patients subsequently treated with a lopinavir/ritonavir based regimen remained on this therapy for up to nine years. © GERMS 2013.
Authors & Co-Authors
Wanless, Richard Sebastian B.
United States, Houston
Baylor College of Medicine
Ruginǎ, Sorin
Romania, Constanta
Ovidius University of Constanta
Ruta, Simona Maria
Romania, Bucharest
Ştefan S. Nicolau Institute of Virology
Dumitru, Magdalena Irina
Romania, Constanta
Ovidius University of Constanta
Cernat, Roxana Carmen
Unknown Affiliation
Schwarzwald, Heidi L.
Unknown Affiliation
Calles, Nancy R.
United States, Houston
Baylor College of Medicine
Schutze, Gordon E.
United States, Houston
Baylor College of Medicine
Draper, Heather R.
United States, Houston
Baylor College of Medicine
Kline, Mark W.
United States, Houston
Baylor College of Medicine
Statistics
Citations: 6
Authors: 10
Affiliations: 3
Identifiers
Doi:
10.11599/germs.2013.1042
ISSN:
22482997
Research Areas
Health System And Policy
Infectious Diseases
Maternal And Child Health
Study Design
Cohort Study